X4 Pharmaceuticals, Inc.
CANCER BIOMARKERS AND METHODS OF USE THEREOF

Last updated:

Abstract:

The present invention relates, in part, to certain cancer biomarkers and use thereof in methods for treating cancer, such as in evaluating and/or predicting patient responses to treatment with a CXCR4 inhibitor optionally in combination with a immunotherapeutic agent, in patients with a cancer such as melanoma, including resectable and unresectable melanoma. The present invention also provides a biomarker expression platform, which is a combination of a set of genes or biomarkers that are correlated with response to a CXCR4 inhibitor in a tumor as well as a normalization gene set. A method and system of using the biomarker expression platform to derive biomarker signatures of anti-tumor response and to test patient samples for predictive biomarker signatures are also disclosed.

Status:
Application
Type:

Utility

Filling date:

6 Nov 2018

Issue date:

11 Nov 2021